Established in 2015
ID4Pharma hold a global patent of sequestosome-1-/p62-targeted specific small molecules which have showed good therapeutic index for Multiple Myeloma treatment. In preclinical studies, our drug molecule has shown high anti-MM efficacy, toxicology safety, no drug resistance, and a good PK bioavailability. Currently, ID4 is to seek strategic partnerships for human clinical trials and then towards MM market globally.
|
Our GoalOur goal is to conduct FDA IND-enabling studies of sequestosome-1 target-specific small molecule drugs in belief that our Anti-MM drug will benefit MM patients with better results and fewer side effects. Therefore we are seeking a strategic Pharma/Biotech partnership, investors, and venture capitalists; We hope to bring our anti-MM drug to market where it will be accessible by patients in need worldwide.
|
Our Team
James J-H Lee, PhD (Drug Medicinal Chemist and Expert)
|
Xiang-qun (Sean) Xie, MD,PhD, EMBA
|
John Zhang, PhD
|
Chris L. Waller, PhD
|
David Roodman, MD, PhD
|
Ying Mu, PhD, D.A.B.T
|
Jing-Zhou Hou MD, PhD
|
Y.T Kwon, PhD.
|
L. Harris Zhang, PhD. EMBA
|
Richard (Rick) Bertz, PhD.
|